Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
12.79
+0.33 (2.65%)
Dec 20, 2024, 4:00 PM EST - Market closed

DAWN Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Selling, General & Admin
107.8875.5461.2929.164.681.01
Research & Development
198.23130.5285.6243.589.113.9
Operating Expenses
306.11206.06146.9172.7413.7814.91
Operating Income
-206.46-206.06-146.91-72.74-13.78-14.91
Interest Expense
-----0.03-2.08
Interest & Investment Income
18.6717.194.750--
Other Non Operating Income (Expenses)
109.16-0.04-0.02-0.02-30.03-0
Pretax Income
-83.62-188.92-142.18-72.75-43.84-16.98
Earnings From Continuing Operations
-84.29-188.92-142.18-72.75-43.84-16.98
Minority Interest in Earnings
---2.113.344.35
Net Income
-84.29-188.92-142.18-70.65-40.51-12.63
Preferred Dividends & Other Adjustments
---99.99--
Net Income to Common
-84.29-188.92-142.18-170.64-40.51-12.63
Shares Outstanding (Basic)
8980653766
Shares Outstanding (Diluted)
8980653766
Shares Change (YoY)
17.15%21.85%77.13%568.42%-6.67%-
EPS (Basic)
-0.95-2.37-2.17-4.62-7.33-2.13
EPS (Diluted)
-0.95-2.37-2.17-4.62-7.33-2.13
Free Cash Flow
-90.24-147.08-109.9-48.54-13.58-4.52
Free Cash Flow Per Share
-1.01-1.84-1.68-1.31-2.46-0.76
EBITDA
-205.5-206.03-146.85-72.72-13.77-
D&A For EBITDA
0.950.040.060.020.02-
EBIT
-206.46-206.06-146.91-72.74-13.78-14.91
Source: S&P Capital IQ. Standard template. Financial Sources.